Share this post on:

Product Name :
R-O3280

Search keywords :
Ro3280

drugId :
null

Target Vo:
Polo like kinase 1

Target Vo Short Name :
PLK1

Moa_Name:
Polo like kinase 1 inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
F. Hoffmann-La Roche Ltd

Active Company_Name :
F. Hoffmann-La Roche Ltd

Active Indication_Name:
Nasopharyngeal Carcinoma

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Preclinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Phospho-JAK2 (Tyr1007/1008) Antibody
ATG4C Antibody
DR5 Antibody: DR5 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 48 kDa, targeting to DR5. It can be used for WB,IP,IHC-P,FC assays with tag free, in the background of Human.

Share this post on:

Author: Interleukin Related